Paraquat Parkinson's Lawsuit 2026 — MDL 3004 Settlement Update

The paraquat Parkinson’s litigation has reached its endgame — and that endgame is a settlement, not a trial.

Syngenta and Chevron signed a confidential settlement framework in August 2024. In March 2026, the court approved a qualified settlement fund. A bellwether trial scheduled for April 2026 was canceled. Syngenta announced it will exit paraquat production entirely by June 2026. With approximately 6,580 cases pending in MDL 3004, the claims administration process is heading toward final distribution.

This post explains what paraquat is, who is at risk, how MDL 3004 is structured, and what farmworkers and agricultural laborers need to do now.

What Is Paraquat — Toxicology and Regulatory Status

Paraquat dichloride is one of the most widely used herbicides in the world — and one of the most toxic. In the United States, it is sold primarily as Gramoxone (Syngenta) and various generic formulations.

Mechanism of toxicity: Paraquat generates reactive oxygen species (ROS) inside cells. In plant tissue, this kills rapidly. In mammalian tissue — particularly lung, kidney, and neural cells — chronic low-level ROS generation may cause oxidative damage. Researchers hypothesize that long-term paraquat exposure damages dopaminergic neurons in the substantia nigra, the cell population whose loss causes Parkinson’s disease.

Regulatory status — United States: Paraquat is classified by the EPA as a restricted-use pesticide (RUP). It may only be purchased and applied by EPA-certified applicators. Restrictions were tightened in the 2021 Interim Registration Review Decision, which added acreage limits, residential buffer requirements, and mandatory drift management.

Global bans: The European Union banned paraquat in 2007. Brazil banned it in 2020. South Korea in 2012. These bans were based on health and environmental concerns — the same concerns at the heart of U.S. litigation.

Syngenta’s exit: In March 2026, Syngenta confirmed it will stop producing paraquat at its sole global manufacturing facility in Huddersfield, UK, by June 2026. The company attributed this to “generic competition.” The timing — concurrent with settlement negotiations — is notable. Other manufacturers will continue production.

The Science: IARC 2A, Tanner 2011, and the EPA Disagreement

The scientific foundation of the litigation is contested by two major regulatory bodies.

IARC (International Agency for Research on Cancer): Classifies paraquat as Group 2A — probably carcinogenic to humans, with epidemiological associations most prominently for Parkinson’s disease. IARC’s hazard classification does not depend on dose or real-world exposure levels — it asks whether the substance is capable of causing disease.

Tanner et al. (2011): Published in Environmental Health Perspectives, this study of farming communities in Kansas and Iowa found that occupational paraquat or rotenone exposure was associated with approximately 2.5x increased risk of Parkinson’s disease. This study is plaintiffs’ most frequently cited epidemiological anchor.

EPA (Environmental Protection Agency): Does not classify paraquat as a carcinogen or as a cause of Parkinson’s disease. The EPA conducts risk assessment at real-world exposure levels — a different methodology than IARC’s hazard classification. The EPA reauthorized paraquat in 2021, citing sufficient mitigation measures.

This regulatory divergence — one major international body says “probably causes cancer-like neurotoxicity,” the primary U.S. regulatory agency says “manageable risk with mitigation” — is the scientific battlefield that played out in MDL 3004 depositions and expert challenges.

Roundup Non-Hodgkin Lymphoma Lawsuit — IARC 2A Herbicide Comparison

MDL 3004: Structure and Timeline

Item	Detail
MDL Number	3004
Full Title	In re Paraquat Products Liability Litigation
Court	Southern District of Illinois
Presiding Judge	Chief Judge Nancy J. Rosenstengel
Defendants	Syngenta Crop Protection LLC, Chevron U.S.A. Inc.
Case Count	~6,580 (May 2026)
Current Status	Settlement fund approved; distribution pending

Bellwether history: A federal bellwether trial in MDL 3004 was set for October 2025, but Judge Rosenstengel vacated it to allow settlement negotiations to continue. A second scheduled date of April 6, 2026 was also canceled after the court approved the qualified settlement fund.

Philadelphia state court: In parallel state litigation, Syngenta and Chevron settled the first Philadelphia paraquat bellwether case on January 29, 2026, just before jury selection — choosing to avoid a public verdict rather than risk losing. This confidential settlement signals defendants’ strong preference for avoiding jury trials.

My assessment: The settlement-without-trial trajectory in MDL 3004 mirrors how the Roundup MDL ultimately resolved — large consolidated MDL, multiple settlement tranches, no completed federal bellwether verdicts. The difference here is that paraquat plaintiffs are farmworkers and agricultural workers with Parkinson’s disease, a population with less resources for long-term litigation. A global settlement serves both sides’ interests. The question is the individual compensation tiers.

Who Qualifies: Exposure, Diagnosis, and Documentation

Exposure Requirements

Claimants must document direct contact with paraquat or paraquat-containing products in the United States.

Qualifying exposure sources:

• Direct application as a certified or supervised farm applicator
• Mixing, loading, or handling paraquat on a farm, nursery, golf course, or park
• Non-certified use in violation of RUP rules (still compensable; defendants cannot use RUP status as a complete defense)
• Residential proximity to fields with documented drift — though these cases are harder to establish

Documentation to gather:

• Employer pesticide application records
• EPA certified applicator license or employer training records
• Purchase receipts for Gramoxone or paraquat products
• Co-worker declarations
• Medical records noting occupational chemical exposure

Parkinson’s Disease Diagnosis

A formal Parkinson’s disease diagnosis by a neurologist or movement disorder specialist is required. Parkinsonian symptoms without a confirmed clinical diagnosis are insufficient. The earlier in the disease course the diagnosis is documented, the more contemporaneous evidence is available.

Claim Tiers

While specific MDL 3004 tier criteria are subject to confidential negotiations, mass tort medical device and toxic exposure settlements typically create tiers based on:

• Severity of Parkinson’s symptoms (Hoehn-Yahr staging scale)
• Duration and intensity of paraquat exposure
• Age at onset
• Whether the plaintiff is still working or disabled

Higher tiers correspond to greater functional impairment and stronger exposure documentation.

Exposure Type	Likely Tier Impact	Evidence Needed
Daily direct application, 5+ years	Higher	Employer records, applicator license
Periodic application, 1–5 years	Middle	Work records, co-worker statements
Mixing/loading without application	Middle	Employer records
Residential drift, indirect exposure	Lower	USGS spray drift data, property records

Statute of Limitations: The Discovery Rule for Parkinson’s

Parkinson’s disease is progressive and insidious. Many patients experience symptoms for years before receiving a definitive diagnosis, and the causal link to paraquat exposure was not widely publicized until litigation began around 2017.

Most states apply the discovery rule: the statute of limitations begins when the plaintiff knew or reasonably should have known both (1) that they had Parkinson’s disease and (2) that it may have been caused by pesticide exposure. This means:

• Even if you stopped using paraquat 15 years ago, your SOL may only have started running when you received your Parkinson’s diagnosis — or when the paraquat-Parkinson’s link became publicly known in your community.
• State SOLs range from 2–6 years, with tolling rules that vary by state.
• Filing in the MDL does not restart the state SOL for claims not transferred to federal court.

If you are unsure whether your claim is time-barred, consult an attorney immediately. The most common mistake in mass tort cases is assuming it is too late.

Medicare and Medicaid Liens

Parkinson’s disease treatment is expensive — neurology visits, levodopa and other dopaminergic medications, physical therapy, occupational therapy, and eventually long-term care. If Medicare or Medicaid has paid for any of these costs attributable to paraquat exposure, those payors have subrogation rights under the Medicare Secondary Payer Act (MSP).

Lien amounts are typically negotiated down by your attorney before you receive a net payout from settlement. In Parkinson’s cases with years of treatment, lien reduction negotiation can add tens of thousands of dollars to net recovery. Ensure your attorney has a lien management process.

What Farmworkers Should Do Right Now

Settlement fund approval does not mean automatic payment. A formal claims administration process will open with documentation deadlines. Missing those deadlines means missing the settlement entirely.

Immediate steps:

1. Document your exposure — gather employer records, chemical training certifications, purchase receipts, and any records showing paraquat product use at your workplace
2. Secure your Parkinson’s records — neurologist diagnosis letter, MRI/CT reports if any, medication prescription history, functional assessment
3. Consult a mass tort attorney — most offer free initial consultations on contingency; look for attorneys with MDL 3004 specific experience through the AAJ

Camp Lejeune Water Contamination Lawsuit — Comparing Federal Toxic Exposure Claims

The Roundup vs. Paraquat Comparison

Both are herbicide MDLs with IARC Group 2A classifications. Both name agricultural chemical manufacturers as defendants. Their litigation paths differ significantly.

Item	Roundup (MDL 2741)	Paraquat (MDL 3004)
Defendant	Bayer (Monsanto)	Syngenta + Chevron
Disease	Non-Hodgkin Lymphoma	Parkinson’s Disease
IARC	Group 2A	Group 2A
Bellwether results	3 plaintiff verdicts	No federal verdict; settled
Settlement	~$10.9B framework (2020)	Confidential (2024)
EPA stance	”Not likely carcinogenic”	Not classified as cause

Roundup plaintiffs saw actual jury verdicts — the Johnson, Hardeman, and Pilliod cases — before Bayer agreed to settle. Paraquat defendants moved to settle before any federal verdict. This distinction may affect individual settlement tier values; without a reference verdict establishing damages in trial, the negotiating dynamics differ.

What Comes Next

If the settlement proceeds to final distribution as expected:

1. A formal claims administrator will open an intake process
2. Claimants submit medical and exposure documentation
3. Tier assignment determines individual award amounts
4. A claims period deadline is set — missing it is fatal to recovery

If you have not retained an attorney yet, the window between now and the formal claims deadline is critical. Most reputable mass tort firms are still accepting paraquat-Parkinson’s clients as of May 2026.

Talcum Powder Ovarian Cancer Lawsuit — Comparable Mass Tort for Chemical Exposure Injuries

Understanding the Settlement Tier Structure

While the specific MDL 3004 tier criteria are confidential, the structure of paraquat settlement tiers can be anticipated from prior herbicide and occupational exposure MDLs.

Mass tort settlement programs typically tier claims based on:

Exposure Factors

• Duration of direct exposure (years of use)
• Frequency (daily application vs. occasional)
• Application method (mixing and loading vs. tractor-spray vs. hand spray)
• Use of personal protective equipment (PPE) — or lack thereof
• Certified applicator status

Medical Factors

• Parkinson’s disease diagnosis confirmed by neurologist
• Disease severity at time of claim (Hoehn-Yahr staging: Stage 1 = mild, Stage 5 = severe)
• Age at Parkinson’s onset (younger onset = longer expected loss period)
• Treatment costs documented

Causation Factors

• Evidence linking specific paraquat brand/product to exposure
• Time between exposure and diagnosis (consistent with known latency)

Higher tiers mean larger individual awards. The difference between Tier 1 (indirect, short-duration exposure, mild Parkinson’s) and Tier 3 (direct daily application, years of exposure, advanced Parkinson’s with disability) can be hundreds of thousands of dollars.

Parkinson’s Disease: The Medical Case to Document

Parkinson’s disease is a progressive neurodegenerative disorder characterized by motor symptoms — tremor, rigidity, slowness of movement (bradykinesia), postural instability — that result from the loss of dopaminergic neurons in the substantia nigra of the brain.

Diagnosis confirmation: A neurologist or movement disorder specialist’s diagnosis carries far more weight than a primary care provider’s assessment. If you have been diagnosed only by a general practitioner, obtaining a specialist confirmation strengthens your claim.

Staging documentation: The Hoehn-Yahr scale and the MDS-UPDRS (Unified Parkinson’s Disease Rating Scale) are the standard clinical tools for documenting disease severity. Request that your neurologist document your current staging. Higher stages at time of claim filing generally correspond to higher settlement tier assignments.

Imaging: While Parkinson’s disease is a clinical diagnosis (brain MRI is typically normal), some patients have DaTscan (dopamine transporter SPECT imaging) that can support the diagnosis. If you have had any brain imaging, preserve those records.

Medication history: Levodopa/carbidopa (Sinemet), dopamine agonists (pramipexole, ropinirole), MAO-B inhibitors (rasagiline, selegiline) — the prescription record of these medications over time documents disease progression and treatment cost.

The Ninth Circuit EPA Challenge: A Background Legal Battle

While MDL 3004 moved toward settlement, a separate legal battle over paraquat’s regulatory status played out in the Ninth Circuit Court of Appeals.

Environmental and farmworker advocacy organizations, including the California Rural Legal Assistance Foundation, challenged the EPA’s 2021 Interim Registration Review Decision that reauthorized paraquat. In early 2025, the EPA filed for voluntary remand — asking the court to return the matter to the EPA for reconsideration — which the court granted.

This regulatory litigation has run parallel to (and independent of) the civil MDL. The outcome of the EPA’s paraquat review does not directly determine civil liability, but it affects the regulatory backdrop against which damages arguments are made. An EPA finding that paraquat requires more restrictive controls — or should be banned — would strengthen plaintiffs’ narrative in future litigation, even if it has no legal effect on the MDL 3004 settlement.

Syngenta’s Corporate Context: ChemChina and Global Obligations

In 2017, Syngenta was acquired by ChemChina, a state-owned Chinese enterprise, in a $43 billion transaction. This corporate lineage matters for settlement enforcement.

If the MDL 3004 settlement is finalized and Syngenta’s U.S. subsidiary (Syngenta Crop Protection, LLC) enters into a binding settlement agreement, enforcement follows normal U.S. contract and court order procedures. The Chinese parent’s ownership does not create additional complexity for U.S. court-ordered settlements.

Chevron U.S.A., as a wholly owned subsidiary of Chevron Corporation, has the financial resources of one of the world’s largest energy companies backing any settlement obligations — this is not a settlement where collectability risk is a meaningful concern.

Agricultural Communities Disproportionately Affected

The geography of paraquat exposure maps closely onto agricultural communities throughout the American South, Midwest, and West — particularly in states like California (Central Valley), Florida (citrus and vegetables), Texas (cotton), North Carolina (tobacco), and Washington (fruit orchards).

Within these communities, Hispanic and Latino agricultural workers are statistically overrepresented as paraquat applicators. The 2021 National Agricultural Workers Survey estimated that approximately 73% of hired crop workers in the U.S. are Hispanic or Latino. Many work on farms that historically used paraquat.

Language and documentation barriers have historically delayed these workers from seeking legal counsel. By the time Parkinson’s disease is diagnosed and the connection to paraquat is understood, years may have passed. This is why the discovery rule tolling principle is so critical for this population — and why bilingual legal representation matters.

What Happens After You File: The MDL Claims Administration Process

Once the formal claims administration process opens for MDL 3004, here is what claimants can expect:

Step 1: Registration — Your attorney registers your claim with the claims administrator. This requires basic identifying information and a preliminary description of your exposure and diagnosis.

Step 2: Eligibility Review — The administrator verifies that you meet minimum eligibility criteria (U.S. exposure to paraquat, Parkinson’s diagnosis). Claims that fail this review are kicked out.

Step 3: Documentation Submission — You submit medical records (Parkinson’s diagnosis and staging), exposure records (employer pesticide use logs, applicator certifications), and any supporting documentation.

Step 4: Tier Assignment — The administrator assigns your claim to a settlement tier based on the documentation submitted. You (through your attorney) may dispute the assignment.

Step 5: Acceptance or Rejection — You decide whether to accept the tier assignment and the corresponding settlement amount. Rejecting the offer means your claim exits the settlement program — and you likely lose the opportunity to recover through this route.

Step 6: Disbursement — After acceptance, the settlement fund disburses payment, minus attorney fees and lien repayments. Timeline varies but is typically 3–12 months after acceptance.

ERISA Liens and Self-Funded Health Plans

If your Parkinson’s disease treatment has been covered by an employer-sponsored health plan that is self-funded (ERISA plans), that plan has subrogation rights under federal law. ERISA preempts state anti-subrogation statutes, meaning ERISA plans can enforce their lien against your full settlement recovery regardless of what state law says.

The distinction between a fully insured plan and a self-funded ERISA plan is often invisible to the patient — it is in the Summary Plan Description. Your attorney will identify this. Experienced mass tort firms negotiate ERISA liens down, often recovering 50–80 cents on the dollar for the lienor, which increases your net.

Wrongful Death Lawsuit Settlement — When Parkinson’s Disease Causes Fatal Complications

Employer Liability: Can Farms and Golf Courses Also Be Sued?

In addition to suing Syngenta and Chevron as product manufacturers, individual claimants may have claims against employers if the employer:

• Provided paraquat without required training
• Failed to provide required PPE
• Violated EPA restricted-use pesticide requirements
• Negligently supervised pesticide application

These employer claims may be barred by workers’ compensation exclusivity in some states — the “exclusive remedy” doctrine prevents workers from suing their employer in tort when workers’ comp provides coverage. However, exceptions exist for intentional misconduct and for claims not covered by workers’ comp (such as occupational disease in some states).

An attorney evaluating a paraquat case will assess whether employer claims add value alongside the manufacturer claims in MDL 3004.

Workers’ Compensation PTSD Claim — Occupational Disease and Employer Liability Comparison

Frequently Asked Questions from Agricultural Workers

Q: I used paraquat on a farm 20 years ago and was just diagnosed with Parkinson’s. Am I too late?

Likely not. The discovery rule in most states starts your limitations clock at diagnosis — or when you first had reason to know the diagnosis might be linked to paraquat exposure. With the paraquat-Parkinson’s connection not widely publicized until 2017–2021, many courts will find that the clock started running recently, not 20 years ago. Consult an attorney immediately rather than assuming you are time-barred.

Q: I was not a certified applicator — I used paraquat without the required EPA certification. Does that bar my claim?

No. The fact that you or your employer violated EPA’s restricted-use rules does not prevent you from suing the manufacturer. Comparative fault principles may reduce your recovery if your own negligence contributed to exposure, but it does not eliminate the manufacturer’s liability for selling a dangerous product.

Q: My employer told me the paraquat was safe and provided no PPE. Can I sue them too?

Potentially. Workers’ compensation exclusivity may bar some employer tort claims, but exceptions exist for intentional misconduct, failure to provide required PPE, or occupational disease claims in some states. Your attorney will assess both the manufacturer MDL claim and any employer-based claim.

Q: The settlement is confidential — how will I know what to expect?

Once the formal claims administration process opens, you will receive information about tier criteria and the corresponding value ranges. You have the right to accept or reject your tier assignment, and your attorney can negotiate on your behalf. Most experienced mass tort firms will have early intelligence about the tier structure from their involvement in MDL proceedings.

Q: Can I participate in both the federal MDL settlement and a state court lawsuit?

Generally no — once you accept a settlement and sign a release, your claims against the settling defendants are resolved. You cannot then pursue a state court case on the same facts against the same defendants. Your attorney will help you evaluate whether the settlement offer is better or worse than your state court prospects.

Camp Lejeune Water Contamination Lawsuit — Federal Toxic Exposure Claim Process